Oruka Therapeutics' (ORKA) Buy Rating Reiterated at BTIG Research

Key Points

• BTIG Research reiterated its Buy rating on Oruka Therapeutics and set a $151 price target, implying 44.41% upside from the stock’s current price.
• Analyst sentiment is broadly positive but not unanimous: MarketBeat reports a “Moderate Buy” consensus and an average $133 target, with ten Buy ratings and one Sell rating.
• Oruka reported a quarterly loss of $0.63 per share, missing estimates of a $0.60 loss. Insiders sold a combined 179,950 shares worth about $16.5 million over the past 90 days, with the cited transactions conducted under pre-arranged trading plans.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "buy" rating restated by BTIG Research in a note issued to investors on Tuesday, Benzinga reports. They presently have a $151.00 price objective on the stock. BTIG Research's price target points to a potential upside of 44.41% from the company's current price.

Other analysts have also recently issued reports about the company. Piper Sandler reaffirmed an "overweight" rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Wall Street Zen cut shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Guggenheim restated a "buy" rating and issued a $200.00 price target on shares of Oruka Therapeutics in a research report on Monday, October 26th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $133.00.

Oruka Therapeutics Trading Up 1.7%

Shares of ORKA stock opened at $104.56 on Tuesday. The company's fifty day simple moving average is $88.48 and its two-hundred day simple moving average is $70.92. Oruka Therapeutics has a 52 week low of $25.23 and a 52 week high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). On average, sell-side analysts forecast that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 9,999 shares of the company's stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $80.60, for a total transaction of $805,919.40. Following the sale, the senior vice president directly owned 14,219 shares in the company, valued at $1,146,051.40. This represents a 41.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $74.81, for a total value of $523,670.00. Following the completion of the sale, the insider directly owned 31,771 shares of the company's stock, valued at $2,376,788.51. The trade was a 18.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 179,950 shares of company stock valued at $16,492,680 over the last ninety days. 23.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC lifted its holdings in Oruka Therapeutics by 4.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,991 shares of the company's stock valued at $333,000 after buying an additional 168 shares in the last quarter. Algert Global LLC grew its stake in Oruka Therapeutics by 3.5% in the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company's stock worth $512,000 after acquiring an additional 180 shares in the last quarter. AlphaCentric Advisors LLC grew its stake in Oruka Therapeutics by 3.4% in the 3rd quarter. AlphaCentric Advisors LLC now owns 6,752 shares of the company's stock worth $562,000 after acquiring an additional 221 shares in the last quarter. GAMMA Investing LLC grew its stake in Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company's stock worth $31,000 after acquiring an additional 250 shares in the last quarter. Finally, Nykredit A S purchased a new position in shares of Oruka Therapeutics during the second quarter worth approximately $29,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments.

The company's pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Oruka was established around antibody programs developed by Paragon Therapeutics and became a publicly traded company in 2024 through a business combination with ARCA biopharma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.